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Introduction and Clinical Pathology 
Amyotrophic lateral sclerosis (ALS) is a prototypic, age- 
dependent neurodegenerative disorder. It typically afflicts 
individuals in middle adult life, leading to paralysis and 
death within 3 to 5 years (Williams and Windebank, 1991). 
The disease usually begins asymmetrically and distally in 
one limb, most commonly the leg, and then appears to 
spread within the neuraxis to involve contiguous groups 
of motor neurons. Pathologically, ALS is distinguished by 
atrophy and death of the affected neurons, with dissolution 
of both cytoplasm and nuclei. The motor neuron death 
process appears to be cell autonomous; autopsy studies 
reveal no evidence that other cell types participate in killing 
motor neurons. Many affected neurons demonstrate evi- 
dence of cytoskeletal pathology in the form of accumula- 
tions of neurofllaments, both within the neuronal cell body 
and in axons. Aggregates of ubiquitinated, unidentified 
proteins are also seen, as is subtle proliferation of glial 
cells (Leigh and Swash, 1991). Recent investigations have 
implicated oxidative cytotoxicity in the pathogenesis of a 
familial form of ALS (FALS). This review considers the 
evidence that this disease arises from oxidative and exci- 
totoxic injury to critical subcellular targets in motor neu- 
rons and summarizes current hypotheses concerning the 
mechanism of motor neuron death in ALS. 
Possible Causes of Motor Neuron Disease 
As with any neurodegenerative disorder, etiologic hypoth- 
eses in ALS must explain three essential aspects of the 
disease: the mechanisms and pathways leading to cell 
death, the selectivity of the process for the affected neu- 
rons, and the onset in adulthood. While many hypotheses 
have been advanced to explain the pathogenesis of ALS, 
as reviewed by Rowland (1991), few have adequately ex- 
plained each of these aspects. The motor neuron selectiv- 
ity of poliovirus has prompted the theory that ALS might 
represent an atypical polioviral infection; to date, tradi- 
tional culturing methods and in situ RNA hybridization 
have failed to detect poliovirus in ALS cerebrospinal fluid 
and brain specimens. The possibility that ALS might be 
a form of slow viral infection has not been supported by 
long-term studies of inoculation of ALS brain tissues into 
nonhuman primates. Because they may induce clinical 
paralysis and motor nerve pathology in some experimental 
animals, lead, aluminum, and other metallotoxins have 
also been implicated. Thus far, however, no convincing 
clinical or necropsy data support this hypothesis in con- 
ventional ALS. Both spinal and corticospinal motor neuron 
degeneration can be induced as autoimmune diseases. 
This and other observations have occasioned the hypothe- 
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sis that ALS may arise on an autoimmune basis. While 
sera of many patients with sporadic ALS possess autoanti- 
bodies that react with constituents of the distal motor termi- 
nal, including voltage-dependent calcium channels, it has 
not been demonstrated that these are causal. Moreover, 
patients with ALS show no benefit from immunosuppres- 
sive therapy, although this does not rigorously preclude 
an autoimmune etiology. Several lines of inquiry indicate 
that toxicity from excitatory neurotransmitters such as glu- 
tamate may be one factor in the pathobiology of ALS. Brain 
tissue levels of glutamate are depressed (e.g., Perry et al., 
1987), while cerebrospinal fluid glutamate and aspartate 
levels may be elevated both in sporadic human ALS pa- 
tients (Rothstein et al., 1990; cf. Perry et al., 1990) and 
in canine motor neuron disease (Tsai et al., 1993). Addi- 
tionally, glutamate transport is diminished in synapto- 
somal preparations from ALS brains (Rothstein et al., 
1992). Recently, genetic studies have delineated two pro- 
teins that are defective in some cases of ALS: superoxide 
dismutase (SOD) and neurofilament heavy chains. As ar- 
gued below, several lines of investigation prompted in part 
by these genetic findings suggest the hypothesis that the 
motor neuron death process in ALS reflects a complex 
interplay among oxidative injury, excitotoxic stimulation 
of the motor neuron, and dysfunction of mitochondria nd 
critical proteins such as neurofilaments. 
SOD1 and ALS 
Two forms of ALS are inherited. The predominant form, 
transmitted as an autosomal dominant trait, is an adult- 
onset disease that is clinically and pathologically indistin- 
guishable from sporadic ALS. About 10%-15% of all ALS 
cases fall within this category. In recent years, there has 
also been recognized a rare, recessively inherited child- 
hood-onset form of ALS associated with very long survival 
(Ben Hamida et al., 1990). The clinical and pathological 
similarity between the dominantly inherited and sporadic 
forms of ALS prompted a multicenter effort to identify one 
or more ALS genes on the premise that insights into the 
inherited disease might illuminate the pathogenesis of 
sporadic ALS. In 1991, an ALS locus was identified on 
human chromosome 21q, although only a fraction of all 
ALS families were linked to this region (Siddique et al., 
1991). In 1993, a gene within this region encoding the 
protein cytosolic copper-zinc SOD (SOD1) was found to 
be mutated in several ALS families (Rosen et al., 1993). 
At present, more than 20 missense mutations in SOD1 
have been reported exclusively in FALS patients. The 
product of SOD1 is a metalloenzyme of 153 amino acids 
(Fridovich, 1986). It is thought o be expressed in all eukar- 
yotic cells and is one of a family of three SOD enzymes, 
which also include manganese-dependent mitochondrial 
SOD (SOD2) and copper-zinc extracellular SOD (SOD3). 
SOD1 is encoded by five exons and forms a globular pro- 
tein that functions as a homodimer (Levanon et ai., 1985). 
Within each monomer there is a cave-like active site con- 
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Figure 1. Selected Normal Reactions of Superoxide Anion 
(Top) The superoxide anion (02"-) can react with SOD 1 to be detoxified 
to form hydrogen peroxide (H202) that, in turn, is converted to water 
through the action of catalase and glutathione peroxidase. Superoxide 
may also combine with nitric oxide (NO-) to form peroxynitrite 
(ONOO-). Peroxynitrite may then breakdown onenzymatically to pro- 
due hydroxyl radicals (OH .), which may also be generated from hydro- 
gen peroxide via Fe 2÷ (Fenton reaction). 
(Bottom) These reactive oxygen species may cause oxidative degrada- 
tion of DNA, lipids, and proteins. 
of this enzyme is believed to be the detoxification or dism u- 
tation of the superoxide anion to form hydrogen peroxide 
(Figure 1). This, in turn, is detoxified by either glutathione 
peroxidase or catalase to form water. As shown in Figure 
1, under normal circumstances, superoxide anion can also 
react with nitric oxide to form peroxynitrite (Koppenol et 
al., 1992). One major implication of this biochemical profile 
of SOD1 reactivity is that FALS may be a consequence 
of disturbed free radical homeostasis and cytotoxicity by 
reactive oxygen species. 
Over the last year, several studies have begun to define 
the effects of the FALS mutations on SOD1 function, al- 
though many critical questions remain unanswered. It is 
now clear that the mutations reduce total cellular activity 
of the enzyme by 25% -50% , as analyzed in red blood 
cells, lymphoblastoid cell lines, and brain (Deng et al., 
1993; Bowling et al., 1993; Robberecht et al., 1994). Analy- 
sis of cytoplasmic SOD activity in both lymphoid and COS 
cells has established that the loss of activity does not arise 
from a dominant negative interaction of mutant and wild- 
type protein in SOD1 heterodimers. Rather, the loss of 
function is due to diminished stability of the mutant protein 
per se; depending on the specific mutations, the half-lives 
of the mutant proteins are reduced by 30o-75% (Borchelt 
et al., 1994). 
These observations present a conundrum. Most dis- 
eases arising from inactivity of a protein or from so-called 
loss of function are recessive, as most proteins exist in 
sufficient abundance that their levels must be significantly 
reduced (typically, <5o--10% of normal) before a cellular 
phenotype results. On the other hand, dominantly inher- 
ited diseases, like FALS, are usually thought to arise be- 
cause a single mutant allele produces a mutant protein 
with a novel property that may be injurious to the cell. In 
the context of FALS, the fundamental question is whether 
the motor neuron degeneration arises purely from loss 
of SOD1 activity, which clearly occurs for some of the 
mutations, or from gain of a novel adverse function. This 
has an important therapeutic ramification: ifthe disease is 
a consequence of diminished function of the SOD1 protein 
(i.e., decreased dismutation of the superoxide anion or 
diminished binding of copper and zinc), therapies that aug- 
ment levels of SOD1 activity may be beneficial in FALS 
(Table 1). 
Firm conclusions are not yet possible, but two somewhat 
conflicting lines of investigation are relevant. It has re- 
cently been shown in chronic, organotypic spinal cord cul- 
tures that partial reduction of activity of SOD1 by chronic 
application of SOD1 antisense oligonucleotides triggers 
neuronal death, including fulminant motor neuron death. 
Strikingly, the death process, which is reversed by agents 
that enhance intracellular antioxidant defenses (e.g., 
N-acetylcysteine), is apoptotic (Rothstein et al., 1994). 
Similar results have been observed in cultures of PC12 
cells (Troy and Shelanski, 1994). Because they are chroni- 
cally incubated in supraphysiologic levels of oxygen, it is 
probable that these cultured neurons are under chronic 
oxidative stress and therefore not fully representative ofneu- 
rons in vivo. Nonetheless, a cautious interpretation of these 
experiments is that, under certain conditions, diminished 
levels of SOD1 activity jeopardize survival of neurons. 
By contrast with the foregoing experiments, compelling 
data from at least three laboratories indicate that the FALS 
mutations in SOD1 may act through cytotoxic, possibly 
novel functions (Gurney et al., 1994; Price et al., 1994; 
Ripps et al., 1995). As demonstrated by Gurney et al. 
(1994), mice that overexpress high levels of mutant SOD1 
protein develop a denervating, paralytic process that re- 
sembles ALS both clinically and pathologically. As the pa- 
ralysis develops in these animals, dendritic processes in 
motor neurons show microvacuolization, interpreted to re- 
sult from defects in rough endoplasmic reticulum and mito- 
chondria (Dal Canto and Gurney, 1994). Some mitochon- 
dria show extensive and unusual separation of the inner 
and outer mitochondrial membranes. Because the levels 
of total or aggregate SOD1 activity in these animals are 
greater than normal, it is difficult o argue that the disease 
arises from loss of function, unless there is some type of 
highly focal subcellular loss of function.The possibility 
that the high levels of SOD1 activity in the animals trigger 
the neuronal degeneration is unlikely, as mice overex- 
pressing normal SOD1 to a similar extent do not develop 
motor neuron disease. Thus, a plausible interpretation of 
the motor neuron disease in these mice is that the mutant 
SOD1 molecule is in some way cytotoxic. 
Further support for the argument hat the SOD1 muta- 
tions kill motor neurons via gain of a novel function rather 
than loss of function is the absence, to date, of clear null 
mutations in SOD1 in FALS patients. If haploinsufficiency 
(50% reduction in activity from loss of'the product:of one 
allele) causes the disease, one would anticipate finding 
some mutations that prevent protein expression from the 
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Table 1. Possible Mechanisms of Neuronal Death in FALS with SOD1 Mutations 
Entails Responsive 
Oxidative to SOD1 
Mechanism Toxicity Replacement 
Change or gain of function 
Enzyme is insoluble and toxic 
Altered substrate and product (e.g., peroxynitrite) 
Loss of function 
Increased levels, toxicity of superoxide anion 
Diminished copper binding --* copper toxicity 
Diminished zinc binding -,- zinc toxicity 
Increased peroxynitrite formation 
Increased protein itration 
Increased hydroxyl radical formation 
No No" 







a It is conceivable that SOD1 replacement may be beneficial ifthe wild-type or normal protein can, in some way, counteract the toxic properties 
of the mutant molecule (e.g., by competing for a binding site on a critical target molecule). That this is theoretically possible is suggested by 
analyses of dominantly inherited gene defects in nematodes that demonstrate hat the phenotype of an animal heterozygous for mutant and 
wild-type proteins is usually less pronounced than that for either mutant/null heterozygotes or mutant/mutant homozygotes (Park and Horvitz, 
1986). 
mutant allele (e.g., by introducing premature stop codons 
or deletions of the gene). Such null mutants are conspicu- 
ously absent. One candidate for a null SOD1 mutation, a 
2 bp deletion, is predicted to introduce a premature stop 
codon that would truncate 23 amino acids from the 3' end 
of the molecule (Pramatarova et al., 1994). However, it is 
not yet clear whether this is a true null mutation, These 
considerations uggest it is unlikely that FALS is caused 
solely, i f at all, by a decrease in SOD1 activity. The central 
question then is what are the mechanisms of cytotoxicity 
of the mutant SOD1 molecule? Is it possible, as recently 
suggested (Tsuda et al., 1994), that different mutations 
may act via different mechanisms? While experimental 
data concerning this point are sparse, several possibilities 
are noted (see Table 1). First, the mutant enzyme may be 
so unstable that it precipitates to form toxic cytoplasmic 
aggregates. Second, the mutant SOD1 molecule may 
have an altered substrate affinity that leads to high levels of 
toxic reaction products. For example, it has been proposed 
that the mutant SOD1 molecule may have an enhanced 
affinity for peroxynitrite and, in consequence, produce ele- 
vated levels of nitronium ions that, in turn, catalyze nitra- 
tion of tyrosines on proteins such as neurofilaments and 
tyrosine kinase receptors (Beckman et al., 1993). Third, 
if the stability of the mutant enzyme is reduced, there may 
be subnormal copper or zinc buffering by the enzyme and 
resulting neurotoxicity from one or both of these metals. 
It is well established that copper is a neurotoxin (Schein- 
berg, 1988); indeed, as a transition metal, it can participate 
in several types of oxidative biochemical reactions. Simi- 
larly, zinc also has the potential to be neurotoxic (Koh and 
Choi, 1988; Ebadi et al., 1990). Concomitantly with these 
abnormal properties, the mutant SOD1 protein may also 
be cytotoxic because its reduced ability to detoxify super- 
oxide anion will result in increased levels of this anion and, 
secondarily, in increased levels of peroxynitrate. The latter 
may be toxic through its ability to nitrate protein-tyrosine 
groups or its nonenzymatic decomposition to produce ni- 
trogen dioxygen and hydroxyl radical. 
Neurofilaments and ALS 
Another central question is why mutations in an enzyme 
that is ubiquitously expressed cause an illness so exqui- 
sitely specific to motor neurons, at least as gauged on 
clinical grounds. While no clear answer is available, it is 
likely that some property of the motor neuron confers a 
particular susceptibility to the effects of the SOD1 defects. 
Like all neurons, the motor neuron is a postmitotic, highly 
differentiated cell with a distinctive, polarized cellular anat- 
omy. Unlike most neurons, motor neurons tend to be very 
large, with extremely high ratios of axonal length to cell 
width (up to 10,000:1 in the case of a lumbosacrat motor 
neuron in an adult). This suggests that particular constit- 
uents of the motor neuron required to maintain this distinc- 
tive morphology, such as cytoskeletal proteins, may be 
essential for long-term motor neuron viability and may be 
critical targets for injury, perhaps by reactive oxygen spe- 
cies in FALS. Indeed, some authors report an early finding 
in sporadic ALS and FALS of neurofilamentous accumula- 
tions in cell bodies and proximal axons (Hirano, 1991). In 
this context, it is striking that two different mutations in 
the heavy chain of neurofilament have recently been asso- 
ciated with ALS in three patients (Figlewicz et al., 1994). 
Because these mutations were not detected in more than 
300 DNA samples from normal controls, they are unlikely 
to be polymorphisms. Itremains to be established whether 
these neurofilament mutations will be present in large se- 
ries of either sporadic ALS or FALS patients. However, 
it is pertinent hat transgenic mice overexpressing either 
normal or mutant neurofilaments develop a motor neuron 
disease phenotype (CSt~ et al., 1993; Xu et al., 1993). 
Moreover, mice that express a point mutation in the light 
neurofilament subunit even more fully reproduce aspects 
of human ALS pathology (Lee and Cleveland, 1994). Fur- 
ther, animals intoxicated with the agent 13-l~-imino-dipro- 
prionitrile develop severe neurofibrillary pathology, partic- 
ularly in the proximal axon, which disrupts axonal transport 
and thereby impairs motor neuron function (reviewed by 
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Figure 2. Relationship among SOD1 Mutations, Excitotoxicity, Mitochondrial Function, and Neurodegeneration i ALS 
In the normal neuron, superoxide is detoxified by SOD1 to hydrogen peroxide that is converted to water by catalase and glutathione. The mechanism 
whereby mutant SOD1 is toxic is not understood. It may be toxic because it is unstable and precipitates within the cytoplasm and axoplasm; 
alternatively, the mutant protein may fail to buffer the neurotoxic metals zinc and copper. Mutant SOD1 may also be cytotoxic because its activity 
is reduced; in this case, increased levels of superoxide anion enhance formation of peroxynitrite that may induce oxidative injury by itself or through 
either the formation of hydroxyl radicals or nitration of tyrosine residues on critical motor neuron proteins. One such set of protein targets are the 
neurofilaments (NF) whose injury (by mutation, oxidative degradation, or extrinsic insults) results in formation of fibrillary spheroids that may disrupt 
axonal transport. In this model, excitatory neurotransmitters such as glutamate augment any of these forms of toxicity by increasing levels of free 
cytosolic calcium and thereby enhancing formation of superoxide and nitric oxide and impairing mitochondrial function. This process of neuronal 
injury may be self-sustaining. Free radicals may compromise the structural integrity of mitochondria nd the neuronal membrane. This leads, 
respectively, to enhanced mitochondrial release of hydroxyl radicals and other reactive oxygen species and to increased fluxes of calcium into 
the neuron from the extracellular space. Moreover, because it is highly lipophilic, nitric oxide can diffuse from one cell to another, thereby triggering 
cell-to-cell spread of the pathologic process (dashed arrow). Conceivably, extrinsic factors such as exogenous toxins might also initiate this cascade 
of events. 
and experimental animals underscore the importance of 
cytoskeletal protein function for motor neuron viability. 
Excitotoxicity and Motor Neuron Selectivity 
Both in the mouse models and in human ALS, it is likely 
that an additional factor beyond the complex cellular mor- 
phology and cytoskeletal function is a critical determinant 
of susceptibility to ALS. After all, the dorsal root ganglia 
of sensory neurons have similarly exaggerated axonal 
lengths but do not degenerate in ALS. An important feature 
distinguishing motor neurons from the dorsal root ganglia 
neurons is the presence of excitatory synapses on the 
former. As stated above, data have implicated toxicity from 
normal excitatory inputs in the pathogenesis of ALS. There 
are several ways in which such glutamatergic excitatory 
synaptic input enhancesthe sensitivityof the motor neuron 
to free radical injury. The central element in neuronal exci- 
totoxcity is an elevation of cytosolic free calcium levels 
that, in turn, activates calcium-dependent enzymes, in- 
cluding proteases and enzymes such as xanthine oxidase 
and phospholipase A2 (which may elevate levels of super- 
oxide anion) or nitric oxide synthase (which forms nitric 
oxide) (Coyle and Puttfarcken, 1993). Indeed, the motor 
neuron may be particularly sensitive to increases in cyto- 
solic calcium levels because, by comparison with other 
types of neurons, it is relatively poor in some calcium- 
binding proteins such as calbinden D-28k and parval- 
bumin (Ince et al., 1993). At least in cultured hippocampal 
neurons, concomitant elevation of nitric oxide and super- 
oxide anion is a sine qua non of excitotoxicity, presumably 
through their combination to form peroxynitrite (Dawson 
et al., 1993; see also Choi, 1993). Thus, as illustrated in 
Figure 2, superoxide anion may be an essential element 
in the pathway to excitotoxic cellular injury. 
Summary Model of Motor Neuron 
Death Process in ALS 
Figure 2 attempts to integrate within a single model the 
relationship among mutations in SOD1, excitotoxic stimu- 
lation, mitochondrial function, and the integrity of the cy- 
toskeleton. It offers an overview of possible mechanisms 
of pathogenesis (oxidative injury to or mutations in critical 
proteins such as neurofilaments, failure of axonal trans- 
port) and a possible basis for motor neuron selectivity 
(complex anatomy of the motor neuron and excitotoxicity). 
The model does not inherently provide an explanation for 
the timing of onset of the disease, although one may spec- 
ulate that age-dependent factors modify the scheme. For 
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example, the normal accumulation of age-dependent oxi- 
dative injury may determine the time at which a superim- 
posed oxidative challenge suffices to trigger irreversible 
pathology in the motor neuron. It is also possible that age- 
related decrements in mitochondrial function progres- 
sively reduce ATP production until motor neuron viability 
is marginal; in this setting, the otherwise inocuous stimuli 
described in Figure 2 might render the motor neuron non- 
viable. 
Three features of this model are noted. First, the pro- 
cesses it depicts are potentially self-reinforcing. For exam- 
ple, if superoxide anion or other reactive radicals impair 
mitochondrial function, these organelles may release re- 
active species that, in turn, injure other cellular structures 
as well as other mitochondria. Indeed, elevation of cyto- 
solic calcium can, by itself, trigger hydroxyl radical release 
from mitochondria (Dykens, 1993). Further, evidence sug- 
gests that as mitochondrial function deteriorates, the po- 
tency of excitotoxic stimuli increases (Beal et al., 1993). 
The possibility that mitochondrial pathology may be an 
element early in the pathogenesis of ALS is predicated 
on the observation (discussed above) that vacuolar distor- 
tion of mitochondria occurs early in the course of the motor 
neuron degeneration in the SOD1 transgenic mice. While 
there is little microscopic evidence for specific pathology 
of mitochondria in ALS in humans, activity of mitochondrial 
complex I activity is increased in brains of patients with 
FALS (Bowling et al., 1993). The processes depicted in 
Figure 2 are also self-sustaining simply because the pro- 
gression of cell death is likely to entail loss of membrane 
integrity and increased cytosolic free calcium levels that 
may, in turn, signal further cytotoxic activity. A second 
feature of this model is that it allows for cell-to-cell spread 
of the pathologic process, an aspect strongly suggested 
by the clinical pattern of disease progression. Thus, the 
model attributes acentral role to nitric oxide in the develop- 
ment of neuronal toxicity. This highly lipophilic substance 
is documented in vitro to pass through membranes and 
cells as readily as oxygen. Once generated in injured mo- 
tor neurons, it may diffuse into neighboring cells wherein 
it may interact with superoxide to trigger an analogous 
series of self-sustaining cytotoxic events (Dawson et al., 
1993). A third point inherent within this model is a role 
for extrinsic cellular phenomena to modulate the process. 
Extracellular factors that stimulate oxidative stress, such 
as exogenous toxins or perhaps trauma to the motor neu- 
ron or spinal cord, may trigger or accelerate this sequence 
of pathological reactions. 
Oxidative Toxicity in Motor Neuron Disease 
The model outlined in Figure 2 does not depend uniquely 
on oxidative injury as a trigger of the pathologic process. 
On the other hand, the fact that SOD1 mutations can cause 
FALS raises this hypothesis and predicts there may be 
heightened oxidative injury in neural tissues of ALS pa- 
tients. Consistent evidence for this does not yet exist. An 
early screen for markers of free radical injury in ALS cere- 
brospinal fluid was unrevealing (Mitchell et al., 1987). By 
contrast, a recent study of brains of sporadic ALS patients 
documented elevated levels ot carbonyl proteins, indicat- 
ing oxidative protein damage (Bowling et al., 1993). Analy- 
ses now in progress of other markers of oxidative injury 
will be pivotal in evaluating the role of oxidative stress in 
the motor neuron death process in ALS. 
Concluding Questions and Future Directions 
These investigations of sporadic ALS and of FALS high- 
light the importance of several possible determinants of 
motor neuron viability, including free radical homeostasis, 
critical motor neuron organelles and proteins, and excit- 
atory neural inputs on the motor neuron. Exactly how im- 
portant each of these factors is should become apparent 
from studies addressing several critical questions. One is 
whether, in any form of motor neuron disease, there is 
unequivocal oxidative injury within the nervous system, 
beyond that which accumulates during normal aging. 
Quite simply, the question remains: is ALS a free radical 
disease? If FALS is caused by a novel function of the 
mutant SOD1 protein, what is the function? Further, what 
other genes are defective in FALS cases not arising from 
SOD1 mutations? Will these also implicate oxidative pa- 
thology? Will the pathogenetic mechanisms delineated in 
FALS prove relevant o understanding the more common 
sporadic forms of the disease? Is the motor neuron death 
process in ALS apoptotic or necrotic? If it is apoptotic, can 
it be slowed with antiapoptotic agents such as Bcl-2 or 
cysteine protease inhibitors? One hopes that the insights 
gleaned through these questions will be pertinent not only 
to ALS but also to other neurodegenerative diseases. Most 
importantly, one anticipates that such studies will lead ulti- 
mately to effective strategies for slowing or reversing the 
death of motor neurons in ALS patients. 
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